James Galligan is a professor of pharmacology and toxicology, as well as the director of the Neuroscience Program at MSU. His research focuses on identifying the unique mechanisms of neurotransmission that allow the enteric nervous system to control gut function.
Galligan can speak on a number of topics related to prescription drugs and opioids and the effect these substances have on people.
Industry Expertise (4)
Areas of Expertise (4)
Michigan State University Distinguished Faculty Award (professional)
Up to ten awards are granted annually to faculty members for outstanding total service to the University. These awards are typically granted to faculty who have demonstrated distinction in a combination of teaching, research and service/outreach activities. Over the years, the awards have gone to those senior faculty who are considered to be among the University's finest teachers and scholars.
University of Arizona: PhD, Pharmacology and Toxicology 1983
Rutgers University: MS, Physiology 1978
St. Michael’s College: BA, Biology and Psychology 1976
- American Gastroenterological Association Research Policy Committee
- American Neurogastroenterology and Motility Society
What Is Naloxone?
Women's Health online
"The drug works by binding to opioid receptors in your body and reversing or blocking the effects of opioids like heroin, morphine, or hydrocodone, among others, according to James J. Galligan, Ph.D., a professor of pharmacology and toxicology and director of the neuroscience program at Michigan State University..."
Journal Articles (1)
Jan Tack, M Camilleri, Lei Chang, WD Chey, JJ Galligan, BE Lacy, S Müller‐Lissner, EMM Quigley, J Schuurkes, JH Maeyer, V Stanghellini
The nonselective 5-HT 4 receptor agonists, cisapride and tegaserod have been associated with cardiovascular adverse events (AEs). Aim To perform a systematic review of the safety profile, particularly cardiovascular, of 5-HT 4 agonists developed for gastrointestinal disorders, and a nonsystematic summary of their pharmacology and clinical efficacy. Methods Articles reporting data on cisapride, clebopride, prucalopride, mosapride, renzapride, tegaserod, TD-5108 (velusetrag) and ATI-7505 (naronapride) were identified through a systematic search of the Cochrane Library, Medline, Embase and Toxfile. Abstracts from UEGW 2006–2008 and DDW 2008–2010 were searched for these drug names, and pharmaceutical companies approached to provide unpublished data. Results Retrieved articles on pharmacokinetics, human pharmacodynamics and clinical data with …